
Pharmacy benefits have historically excluded zzso drugs, resulting in coverage of zzso drugs under the medical zzso zzso zzso and other new drug therapies are often zzso and therefore have not presented cost threats to pharmacy zzso The zzso Food and Drug Administration approval of zzso an oral form of zzso in 1998, and zzso zzso in oral dose form for chronic zzso zzso in 2001, signaled a new period in budget forecasting for pharmacy benefits, particularly for small, zzso employers for whom a drug with a cost of 25,000 dollars per year of therapy for 1 patient could increase total pharmacy benefit costs by zzso or zzso 

To zzso the actual relative costs of the oral chemotherapy drugs in pharmacy benefits in 2006 and identify the history of spending on oral chemotherapy drugs relative to total pharmacy benefit spending for small, zzso employers over the zzso years through May zzso 

zzso pharmacy claims from the database of a pharmacy benefits manager zzso for approximately 500,000 members of small, zzso employer plans were used to calculate the net plan cost of oral chemotherapy drugs relative to total drug benefit costs for the period January 1, 2002, through May 31, zzso Current costs for oral chemotherapy drugs for small employers were compared with an insured health plan of approximately the same number of members for dates of service January 1, 2006, through May 31, zzso 

This descriptive analysis found that oral chemotherapy drugs represented zzso of total drug benefit costs, or approximately zzso dollars per member per month zzso for small, zzso employers in 2002, rising zzso to zzso or approximately zzso dollars zzso in the first 5 months of zzso Members in pharmacy benefit plans sponsored by small employers paid an average zzso cost share for oral chemotherapy drugs in 2006, nearly identical to the average zzso paid by members of an insured health plan of similar size in total membership, versus zzso average cost share for all zzso zzso zzso accounted for zzso of total spending on oral chemotherapy agents in 2002 versus zzso in zzso 

Spending on oral chemotherapy drugs as a proportion of total pharmacy benefit costs has more than doubled, from about zzso in 2002 to zzso in zzso For small, zzso employers, this represents a nearly zzso increase in spending, from about zzso dollars zzso in 2002 to about zzso dollars zzso in zzso 

